Acute Myeloid Leukemia (AML): Symptoms, Diagnosis, and Treatment Advances
When 52-year-old Sarah developed persistent fatigue and noticed unusual bruising on her legs, she attributed it to working long hours and clumsiness. But when she spiked a fever that wouldn’t respond to antibiotics, her doctor ordered blood work. The results showed dangerously low normal blood cells and abnormal immature cells flooding her bloodstream. Diagnosis: acute myeloid leukemia. “I’d never even heard of AML,” Sarah recalled. “I thought leukemia only happened to children.”
Acute myeloid leukemia (AML) is a bone marrow stem cell cancer that is often fatal despite available treatments. Diagnosis, risk assessment, monitoring, and therapeutic management of AML have changed dramatically in the last decade due to increased pathophysiologic understanding, improved assessment technology, and the addition of at least 12 approved therapies PubMed CentralWiley Online Library.
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While survival for younger patients over the last several decades has improved nearly sixfold with the optimization of intensive induction chemotherapy and allogeneic stem cell transplantation, this effect has been largely mitigated in older and less fit patients as well as those with adverse-risk disease characteristics Journal of Hematology & Oncology. With median diagnosis age around 68 years, AML predominantly affects older adults—though it can strike at any age.
Recognizing The Symptoms
Acute myeloid leukemia (AML) is a frequently fatal bone marrow stem cell cancer characterized by unbridled proliferation of malignant marrow stem cells with associated infection, anemia, and bleeding PubMedWiley Online Library. The symptoms reflect bone marrow failure as leukemia cells crowd out normal blood cell production.
Common presentations include: persistent fatigue and weakness (from anemia as red blood cell production fails); frequent infections and fever (as functional white blood cells decline despite high white counts); easy bruising, prolonged bleeding from minor cuts, nosebleeds, and gum bleeding (from thrombocytopenia—low platelet counts); bone pain (from marrow expansion); unexplained weight loss; and pale skin. Unlike chronic leukemias that develop slowly over years, AML progresses rapidly—often within weeks. Symptoms escalate quickly, demanding urgent evaluation.
How Diagnosis Has Evolved
The diagnosis is based on the presence of immature leukemia cells in the blood, and/or bone marrow or less often in extra-medullary tissues. New biological insights have been integrated into recent classification systems PubMed Central. Diagnosis begins with complete blood count showing abnormal results: often very high or very low white blood cell counts, anemia, and thrombocytopenia. Blood smears reveal immature blast cells that shouldn’t circulate in healthy blood.
Bone marrow biopsy confirms diagnosis—typically requiring 20% or more blasts in marrow or blood, though certain genetic abnormalities allow AML diagnosis with lower blast percentages. But modern diagnosis extends far beyond blast counting. Next generation sequencing (NGS) is a massive parallel sequencing technique that analyzes multiple gene variants and is a valuable tool for risk assessment, therapy selection, and measurable residual disease monitoring. The European LeukemiaNet guideline for the diagnosis and management of AML recommends the performance of NGS and the genetic assessment of at least 21 gene mutations PubMed Central.
Comprehensive molecular profiling identifies specific mutations—FLT3, NPM1, IDH1/2, TP53, CEBPA, and others—that drive individual AML cases. These mutations determine prognosis and, increasingly, guide targeted therapy selection. Cytogenetic analysis examines chromosome abnormalities. Together, these tests classify AML into favorable-, intermediate-, and adverse-risk categories, predicting outcomes and informing treatment intensity.
The Treatment Revolution: From One-Size-Fits-All To Precision Medicine
For five decades, AML treatment remained essentially unchanged: intensive chemotherapy with cytarabine plus anthracyclines (the “7+3” regimen), followed by stem cell transplantation for eligible high-risk patients. Then came 2017—a turning point. Since 2017, a turning point in AML research, 12 agents have received regulatory approval for AML in the United States: venetoclax (BCL2 inhibitor); gemtuzumab ozogamicin (CD33 antibody-drug conjugate); midostaurin, gilteritinib, and quizartinib (fms-like tyrosine kinase 3 inhibitors); ivosidenib, olutasidenib, and enasidenib (isocitrate dehydrogenase 1 and 2 inhibitors); oral azacitidine; CPX351; glasdegib (hedgehog inhibitor); and recently revumenib (menin inhibitor; approved November 2024) PubMed.
These targeted agents exploit specific vulnerabilities in AML cells. FLT3 inhibitors attack AML driven by FLT3 mutations (about 30% of cases). IDH inhibitors target IDH1/2-mutant disease (20% of cases). Venetoclax—a BCL-2 inhibitor blocking a protein that helps cancer cells avoid death—combined with hypomethylating agents revolutionized treatment for older/unfit patients who couldn’t tolerate intensive chemotherapy. This combination achieves remission rates of 60-70% in previously untreatable populations.
Many AML subtypes—such as AML with MLL1 rearrangements and mutated NPM1—may benefit from menin inhibitors. To date, only one menin inhibitor has received approval by the FDA for relapsed/refractory AML treatment: Revumenib in 2024. Phase 2 demonstrated an overall response of 63% PubMed Central. For patients whose disease returns after initial treatment, these novel agents provide options where none existed before.
The classical paradigm to achieve cure in AML is first to induce complete remission thereby reducing the leukemia burden by several orders of magnitude, followed by post-remission therapy in the form of chemotherapy and/or allogeneic stem cell transplantation. The choice of the most appropriate induction and post-remission therapy is based on multiple parameters, including patient comorbidities, past medical history, AML cytogenetic and molecular risk profile, measurable residual disease status, as well as donor availability and patient goals of care PubMed CentralWiley Online Library.
Prognosis: Age And Genetics Matter
The estimated 5-year overall survival is 30% and differs greatly between various age groups, reaching 50% in younger patients but is less than 10% in patients older than age 60 Wiley Online Library. However, these statistics reflect older data. With newer targeted therapies, outcomes are improving—particularly for specific molecular subtypes. Favorable-risk AML (with mutations like NPM1 without FLT3-ITD, or core-binding factor abnormalities) may achieve 50-70% cure rates with appropriate treatment. Adverse-risk disease—especially TP53-mutant AML—remains devastatingly difficult to cure despite recent advances, with survival often measured in months.
The message: AML demands urgent recognition and molecular profiling. What was once treated uniformly is now dissected into molecular subtypes, each with tailored therapies. From diagnosis requiring only blast counts to comprehensive genetic profiling, from one chemotherapy backbone to a dozen targeted agents, AML treatment has transformed—offering hope where little existed before.
References
- PMC. Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management. https://pmc.ncbi.nlm.nih.gov/articles/PMC11966364/
- PMC. Advances in the Treatment of Acute Myeloid Leukemia. https://pmc.ncbi.nlm.nih.gov/articles/PMC12109363/
- PubMed. Acute myeloid leukemia management and research in 2025. https://pubmed.ncbi.nlm.nih.gov/39656142/
- Journal of Hematology & Oncology. Recent advances in targeted therapies in acute myeloid leukemia. https://jhoonline.biomedcentral.com/articles/10.1186/s13045-023-01424-6
- American Journal of Hematology. Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. https://onlinelibrary.wiley.com/doi/10.1002/ajh.26822
Observer Voice is the one stop site for National, International news, Sports, Editor’s Choice, Art/culture contents, Quotes and much more. We also cover historical contents. Historical contents includes World History, Indian History, and what happened today. The website also covers Entertainment across the India and World.
